Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
|
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [1] Efficacy of pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with ROS-1 rearrangement
    Zhang, B.
    Chu, T.
    Xu, J.
    Zhang, Y.
    Yan, B.
    Dong, Y.
    Qian, J.
    Qiao, R.
    Wang, S.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S100 - S100
  • [2] Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
    Paweł Krawczyk
    Anna Grenda
    Paulina Terlecka
    Justyna Błach
    Kamila Wojas-Krawczyk
    Tomasz Kucharczyk
    Izabela Chmielewska
    Robert Kieszko
    Bożena Jarosz
    Michał Gil
    Katarzyna Reszka
    Janusz Milanowski
    Scientific Reports, 11
  • [3] Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
    Krawczyk, Pawel
    Grenda, Anna
    Terlecka, Paulina
    Blach, Justyna
    Wojas-Krawczyk, Kamila
    Kucharczyk, Tomasz
    Chmielewska, Izabela
    Kieszko, Robert
    Jarosz, Bozena
    Gil, Michal
    Reszka, Katarzyna
    Milanowski, Janusz
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [4] Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
    Zhu, You-Cai
    Wan, Bing
    Wu, Li-Xin
    Li, Xing-Liang
    Wang, Wen-Xian
    Xu, Chun-Wei
    Zhuang, Wu
    Wei, Jian-Guo
    Du, Kai-Qi
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (04) : 1630 - 1634
  • [5] FISH Analysis of Crizotinib Target Genes MET/ALK/ROS-1 in Malignant Mesothelioma
    Fedeli, Franco
    Salvi, Sandra
    Boccardo, Simona
    Varesano, Serena
    Dessanti, Paolo
    Valentino, Alessandro
    Ferro, Paola
    Canessa, Pier Aldo
    Ravetti, Jean Louis
    Pistillo, Maria Pia
    Roncella, Silvio
    MODERN PATHOLOGY, 2017, 30 : 478A - 478A
  • [6] FISH Analysis of Crizotinib Target Genes MET/ALK/ROS-1 in Malignant Mesothelioma
    Fedeli, Franco
    Salvi, Sandra
    Boccardo, Simona
    Varesano, Serena
    Dessanti, Paolo
    Valentino, Alessandro
    Ferro, Paola
    Canessa, Pier Aldo
    Ravetti, Jean Louis
    Pistillo, Maria Pia
    Roncella, Silvio
    LABORATORY INVESTIGATION, 2017, 97 : 478A - 478A
  • [7] Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
    Mazieres, Julien
    Zalcman, Gerard
    Crino, Lucio
    Biondani, Pamela
    Barlesi, Fabrice
    Filleron, Thomas
    Dingemans, Anne-Marie C.
    Lena, Herve
    Monnet, Isabelle
    Rothschild, Sacha I.
    Cappuzzo, Federico
    Besse, Benjamin
    Thiberville, Luc
    Rouviere, Damien
    Dziadziuszko, Rafal
    Smit, Egbert F.
    Wolf, Jurgen
    Spirig, Christian
    Pecuchet, Nicolas
    Leenders, Frauke
    Heuckmann, Johannes M.
    Diebold, Joachim
    Milia, Julie D.
    Thomas, Roman K.
    Gautschi, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 992 - +
  • [8] Lung Adenocarcinoma with Concurrent KRAS Mutation and ALK Rearrangement Responding to Crizotinib
    Zhu, Y.
    Wang, W.
    Xu, C.
    Li, X.
    Zhuang, W.
    Du, K.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1050
  • [9] Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations.
    Liu, Jun
    Cui, Shaohua
    Jiang, Liyan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] NCOA1-ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
    Cao, Qi
    Liu, Zhiguang
    Huang, Yanhua
    Qi, Chuang
    Yin, Xiaowei
    ONCOTARGETS AND THERAPY, 2019, 12 : 1071 - 1074
12345